Research analysts at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The stock’s fifty day simple moving average is $0.07. The firm has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45.
About Nabriva Therapeutics
See Also
- Five stocks we like better than Nabriva Therapeutics
- How to Evaluate a Stock Before BuyingÂ
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Pros And Cons Of Monthly Dividend Stocks
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- How to Calculate Inflation Rate
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.